NASONEX Drug Patent Profile
✉ Email this page to a colleague
When do Nasonex patents expire, and when can generic versions of Nasonex launch?
Nasonex is a drug marketed by Organon Llc and Perrigo Pharma Intl and is included in two NDAs.
The generic ingredient in NASONEX is mometasone furoate. There are thirty drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nasonex
A generic version of NASONEX was approved as mometasone furoate by PADAGIS US on March 18th, 2002.
Summary for NASONEX
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 79 |
Clinical Trials: | 60 |
Patent Applications: | 5,359 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for NASONEX |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NASONEX |
What excipients (inactive ingredients) are in NASONEX? | NASONEX excipients list |
DailyMed Link: | NASONEX at DailyMed |
Recent Clinical Trials for NASONEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Yingu Pharmaceutical Co., Ltd | Phase 4 |
Centre hospitalier de l'Université de Montréal (CHUM) | Phase 4 |
EMS | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for NASONEX
Paragraph IV (Patent) Challenges for NASONEX
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NASONEX | Nasal Spray | mometasone furoate | 50 mcg/ Spray | 020762 | 1 | 2009-08-07 |
US Patents and Regulatory Information for NASONEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Perrigo Pharma Intl | NASONEX 24HR ALLERGY | mometasone furoate | SPRAY, METERED;NASAL | 215712-001 | Mar 17, 2022 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NASONEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NASONEX
See the table below for patents covering NASONEX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 162770 | ⤷ Try a Trial | |
Austria | 216243 | ⤷ Try a Trial | |
Croatia | P920383 | MOMETASONE FUROATE MONOHYDRATE, PROCESS FOR MAKING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAID COMPOUND | ⤷ Try a Trial |
Czech Republic | 9300383 | ⤷ Try a Trial | |
Austria | 519489 | ⤷ Try a Trial | |
Japan | H09501700 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NASONEX
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0548114 | SPC/GB97/064 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410 |
0057401 | 94C0002 | Belgium | ⤷ Try a Trial | PRODUCT NAME: MOMETASONI FUROAS; NAT. REG.: 304 S 131 F 7 19930813; FIRST REG.: GR 10681/89 19900622 |
3043773 | 2190041-0 | Sweden | ⤷ Try a Trial | PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; NAT. REG. NO/DATE: MT NR 60226 20210519; FIRST REG.: AT APPROVAL NR 140638 20210426 |
0548114 | 980012 | Netherlands | ⤷ Try a Trial | 980012, 20110905, EXPIRES: 20160905 |
0548114 | C980012 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: MOMETASONI FUROAS MONOHYDRATUM; NAT. REGISTRATION NO/DATE: RVG 21613 19971209; FIRST REGISTRATION: FR NL22055 19970219 |
0548114 | 19875032 | Germany | ⤷ Try a Trial | PRODUCT NAME: MOMETASON-FUROAT-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 40803.00.00 19980218; FIRST REGISTRATION: FRANKREICH NL 22055 19970219 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |